Experimental HCV Drugs
Experimental HCV Drugs
EASL 2011: Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 25 April 2011 23:54
- Written by Liz Highleyman
Addition of the experimental HCV protease inhibitor ABT-450, boosted with ritonavir, to standard therapy increased the likelihood of complete early virological response at 12 weeks in previously untreated genotype 1 chronic hepatitis C patients.
Idera Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 25 April 2011 23:43
- Written by Idera
Idera Pharmaceuticals has decided to hold off on a planned clinical trial of its experimental hepatitis C drug IMO-2125, pending further toxicity data from ongoing animal studies.
FDA Hearings Next Week on Boceprevir and Telaprevir for HCV
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 23 April 2011 00:18
- Written by FDA
FDA Antiviral Drugs Advisory Committee will hear evidence for boceprevir on April 27 and telaprevir on April 28.
EASL 2011: Tegobuvir Works Well in Triple and Quad Regimens for HCV
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 23 April 2011 13:56
- Written by Liz Highleyman
Gilead's HCV polymerase inhibitor tegobuvir (GS-9190) improved response rates in treatment-naive genotype 1 patients when used in various combinations with pegylated interferon, ribavirin, and the experimental protease inhibitor GS-9256, researchers reported at EASL 2011.
Boosted Danoprevir Improves Response in Prior Null Responders
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 19 April 2011 08:09
- Written by Liz Highleyman
Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced early virological response at week 12, but breakthrough reached 50% for those with genotype 1a. 
More Articles...
- EASL 2011: Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People
- EASL 2011: Pegylated Interferon Lambda Boosts Response with Few Side Effects
- EASL 2011: Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C
- EASL 2011: BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
Web Design and Development by